Two drugs together slowed a hard brain tumor in lab tests
Original title: Synergistic cell-cycle repression by HDAC/EZH2 co-targeting in H3K27-altered diffuse midline glioma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done in animals, not people. Most findings at this stage never become treatments.
This was only done in tumor cells in a dish and in mice.
The short version
Two drugs worked better as a pair than alone against DMG tumor cells.
What was studied. Researchers tested two drugs, panobinostat and tazemetostat, on DMG tumor cells taken from patients. They also tested the pair in mice that had these tumors in the brain.
What they found. The two drugs worked much better together than either one alone. They slowed tumor cell growth and made tumor cells die. They cut the number of cells that can regrow a tumor by more than 90 percent to more than 99 percent. In the mice, the pair shrank the tumors, cut how much the tumor spread along the spine, and helped the mice live longer.
What this means, and what it doesn't
What it could mean: This gives a reason to keep testing these two drugs as a pair for DMG. The team says an earlier drug plan like this helped some patients. This new work helps explain why the pair might work. It does not tell us how well the pair works in people.
What it doesn't mean: This is not a cure, and it is not proof the drugs work in people. Most of this work was done in cells in a dish and in mice. Many things that work in mice do not work in people. This is early lab work, not a treatment you can ask for today. It could take years of testing to find out if it helps.
Source: PubMed, July 24, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.